高级检索
当前位置: 首页 > 详情页

Long-Term Survival Outcomes After Liver Resection for Binodular Hepatocellular Carcinoma: A Multicenter Cohort Study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [a]The 1st Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, SecondMilitaryMedical University, Shanghai, People’s Republic of China, [b]Department of Hepatic Surgery, Tongji Hospital, Huazhong University of Science and Technology,Wuhan, People’s Republic of China, [c]Cancer Biotherapy Center, First Affiliated Hospital, School ofMedicine of Zhejiang University, Zhejiang, People’s Republic of China, [d]Department of General Surgery, Ziyang First People’s Hospital, Sichuan, People’s Republic of China, [e]Department of Hepatobiliary Surgery, Pu’er People’s Hospital, Yunnan, People’s Republic of China, [f]The First Department of General Surgery, the Fourth Hospital of Harbin, Heilongjiang, People’s Republic of China, [g]Department of General Surgery, Liuyang People’s Hospital, Hunan, People’s Republic of China, [h]Department of Hepatobiliary Surgery,Mengchao Hepatobiliary Hospital, FujianMedical University, Fujian, People’s Republic of China, [i]The Second Department of Hepatobiliary Surgery,Meizhou People’s Hospital (Huangtang Hosptial),Meizhou Hospital to Sun Yat-sen University, Meizhou, People’s Republic of China, [j]Department of Surgery, Ohio State University,WexnerMedical Center, Columbus, Ohio, USA, [k]Faculty of Medicine, the Chinese University of Hong Kong, Prince ofWales Hospital, Shatin, N.T., Hong Kong SAR
出处:
ISSN:

关键词: Hepatocellular carcinoma Hepatectomy Overall survival Recurrence-free survival Multicentric origin Intrahepatic metastasis

摘要:
Background The long-term prognosis after liver resection for multinodular (>= 3 nodules) hepatocellular carcinoma (HCC) is generally considered to be unfavorable. However, the role of liver resection for binodular HCC is less investigated. Subjects, Materials, and Methods From a multicenter database, consecutive patients who underwent curative-intent liver resection for binodular HCC and without macrovascular invasion between 2003 and 2015 were retrospectively reviewed. Patients' clinical variables as well as perioperative and long-term survival outcomes were analyzed. Univariable and multivariable analyses were performed to identify the risk factors associated with overall survival (OS) and recurrence-free survival (RFS) after curative resection. Results Of 263 enrolled patients, the perioperative 30-day mortality and morbidity rates were 1.5% and 28.5%. The 1-, 3-, and 5-year OS and RFS rates were 81.5%, 52.4%, and 39.1% and 57.1%, 35.8%, and 26.6%, respectively. Multivariable Cox-regression analyses identified preoperative alpha-fetoprotein level >400 mu g/L, tumor size with a sum of two nodules >8 cm, tumor size ratio of large/small nodule >1.5 (asymmetrical proportion), unilateral hemiliver distribution of two nodules, distance of <= 3 cm between two nodules, and microvascular invasion in any nodule as independent risk factors associated with decreased OS and RFS. Conclusion Liver resection was safe and feasible in patients with binodular HCC, with acceptable perioperative and long-term outcomes. Sum of two tumor sizes, size ratio and distribution, and distance between two nodules were independent risk factors associated with long-term survival outcomes after surgery. These results may guide clinicians to make individualized surgical decisions and estimate long-term prognosis for these patients. Implications for Practice Liver resection was safe and feasible in patients with binodular hepatocellular carcinoma, with acceptable perioperative and long-term outcomes. The sum of two tumor sizes, the size ratio and distribution of the two nodules, and the distance between two nodules were independent risk factors associated with long-term overall survival and recurrence-free survival after liver resection. The results of this study may guide clinicians to make individualized surgical decisions, estimate long-term prognosis, and plan recurrence surveillance and adjuvant therapy for these patients.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 2 区 医学
小类 | 2 区 肿瘤学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 肿瘤学
JCR分区:
出版当年[2018]版:
Q1 ONCOLOGY
最新[2023]版:
Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [a]The 1st Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, SecondMilitaryMedical University, Shanghai, People’s Republic of China,
共同第一作者:
通讯作者:
通讯机构: [a]The 1st Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, SecondMilitaryMedical University, Shanghai, People’s Republic of China, [*1]Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, No. 225, Changhai Rd., Shanghai 200438, People’s Republic of China [*2]Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, No. 225, Changhai Rd., Shanghai 200438, People’s Republic of China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:82482 今日访问量:0 总访问量:681 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号